Contraceptive Drugs Market Research Report - Global Forecast till 2027

Contraceptive Drugs Market Size, Trends and Growth Outlook by Type [Oral Contraceptives (Combined Oral Contraceptive Pills and Progestogen-Only Pills), Topical Contraceptives, Contraceptive Injectables and others], Distribution Channel (Hospital & Clinics, Retail Pharmacy, Online Pharmacy and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/0768-HCR | February 2021 | Region: Global | 95 pages

Contraceptive Drugs Market Scenario


Contraceptive Drugs Market is expected to register 6.8% CAGR during the forecast period, 2019 to 2025, with a market value of USD 16790.02 Million in 2018.


Contraceptives drugs are used to prevent pregnancy and are one of the methods used to control birth. Oral contraceptives are hormonal preparations that may contain combinations of the hormone’s estrogen and progestin or progestin alone.


The contraceptive drugs market is driven by factors such as the need to prevent the rising rate of unintended pregnancies and increasing awareness about contraceptive pills.


Additionally, the rise in government and NGO initiatives to promote contraceptive methods, easy use, and low costs of contraceptive drugs is anticipated to fuel the market growth.


For instance, according to the United Nations study ‘global perspectives on unplanned pregnancies’, globally, more than 41% of the 208 million pregnancies that occur each year are unplanned.


On the other hand, side effects associated with the use of contraceptive drugs is projected to hamper the growth of the market during the assessment period.


Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new product launch to sustain their position in the market.


For instance, in April 2018, Mylan launched generic oral contraceptive Yaz tablets, which supported the company's growth in the global market.


Segmentation


The contraceptive drugs market has been segmented into type, distribution channel, and region.


The global market, based on type, the market is further segmented into oral contraceptives, topical contraceptives, contraceptive injectable, and others.


The oral contraceptives segment is further bifurcated into combined oral contraceptive pills and progestogen-only pills. This segment is expected to hold a major share of the market due to easy consumption, over the counter availability of oral contraceptives, and low costs.


Based on distribution channel, the global market is segmented into hospital & clinics, retail pharmacy, online pharmacy, and others.       


The retail pharmacy segment is anticipated to be the fastest-growing segment due to the increasing over the counter purchase of contraceptive drugs.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The contraceptive drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.


The European contraceptive drugs market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.


 The contraceptive drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.


The contraceptive drugs market in the Middle East & Africa has been divided into the Middle East and Africa.


Key Players


The Key Players in the Global Contraceptive Drugs Market are Bayer AG (Germany), Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), Mylan N.V.(US), Allergan Plc (Ireland), Agile Therapeutics (US), Piramal Enterprises Ltd. (India), GlaxoSmithKline PLC (UK), Johnson & Johnson (US), Novartis AG (Europe), and Sanofi (France).


Regional Market Summary


Global Contraceptive Drugs Market Share by Region, 2018 (%)  Contraceptive Drugs Market


Source: World Health Organization (WHO)


The market in the Americas is expected to dominate the global contraceptive drugs market due to the growing rate of unintended pregnancies and the need to prevent abortions in the region. Growing awareness about contraception in the US and Canada is expected to drive the market growth.


For example, according to an article by the National Center for Biotechnology Information, published in 2017, in the US, 45% of pregnancies are estimated to be unintended each year. Thus, to avoid abortions due to unwanted pregnancies, the use of contraceptive drugs is increasing.


The market in Asia-Pacific is expected to show a considerable amount of growth during the forecast period owing to the growing awareness about contraceptive pills and increasing government initiatives to promote contraceptive methods.


For example, in 2017, the Ministry of Health and Family Welfare of India launched two new contraceptives, a contraceptive pill ‘Chhaya’ and an injectable contraceptive MPA under the ‘Antara’ program.


The market in Europe is expected to show a considerable amount of growth, owing to the increasing number of unintended pregnancies.


The market in the Middle East & Africa is projected to account for the least share of the market due to less awareness about contraceptive drugs in the region.


Contraceptive Drugs Market, by Type



  • Oral Contraceptives

  • Combined Oral Contraceptive Pills

  • Progestogen-Only Pills

  • Topical Contraceptives

  • Contraceptive Injectable

  • Others


Contraceptive Drugs Market, by Distribution Channel



  • Hospital & Clinics

  • Retail Pharmacy

  • Online Pharmacy

  • Others


Contraceptive Drugs Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America




  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe




  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Intended Audience



  • Research and development (R&D) companies

  • Pharmaceutical & biotechnology companies

  • Government research institutes

  • Academic institutes and universities

  • Venture capitalists



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 16790.02 Million
  • 2027: Significant Value
  •   CAGR   6.8% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type and Distribution Channel
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Bayer AG (Germany), Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), Mylan N.V.(US), Allergan Plc (Ireland), Agile Therapeutics (US), Piramal Enterprises Ltd. (India), GlaxoSmithKline PLC (UK), Johnson & Johnson (US), Novartis AG (Europe), and Sanofi (France).
      Key Market Opportunities   increase to avoid unwanted pregnancies and their complication
      Key Market Drivers

  • rising rate of unintended pregnancies
  • increasing awareness about contraceptive pills


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The retail pharmacy segment would lead the market.

    The oral contraceptives segment to lead the Contraceptive Drug Market.

    The Americas have a maximum Contraceptive Drug Market.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Overview

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    Chapter 6. Global Contraceptive Drugs Market, by Type

    6.1 Overview

    6.2 Oral Contraceptives

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.1 Combined Oral Contraceptive Pills

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.2 Progestogen-Only Pills

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3 Topical Contraceptives

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4 Contraceptive Injectable

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 7 Global Contraceptive Drugs Market, by Distribution Channel

    7.1 Overview

    7.2 Hospital & Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3 Retail Pharmacy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4 Online Pharmacy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.5 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 10. Global Contraceptive Drugs Market, by Region

    10.1 Overview

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 Latin America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Overview

    11.2 Competitive Analysis

    Chapter 12. Company Profile

    12.1 Bayer AG

    12.1.1 Company Overview

    12.1.2 Product Type Overview

    12.1.3 Financial Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Pfizer Inc.

    12.2.1 Company Overview

    12.2.2 Product Type Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Teva Pharmaceutical Industries Ltd.

    12.3.1 Company Overview

    12.3.2 Product Type Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Merck & Co., Inc.

    12.4.1 Company Overview

    12.4.2 Product Type Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Mylan N.V.

    12.5.1 Company Overview

    12.5.2 Product Type Overview

    12.5.3 Financial Overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Allergan Plc

    12.6.1 Company Overview

    12.6.2 Product Type Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Agile Therapeutics

    12.7.1 Overview

    12.7.2 Product Type Overview

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Piramal Enterprises Ltd.

    12.8.1 Overview

    12.8.2 Product Type Overview

    12.8.3 Financial Overview

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 GlaxoSmithKline PLC

    12.9.1 Overview

    12.9.2 Product Type Overview

    12.9.3 Financial Overview

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Johnson & Johnson

    12.10.1 Overview

    12.10.2 Product Type Overview

    12.10.3 Financial Overview

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 Novartis AG

    12.11.1 Overview

    12.11.2 Product Type Overview

    12.11.3 Financial Overview

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.12 Sanofi

    12.12.1 Overview

    12.12.2 Product Type Overview

    12.12.3 Financial Overview

    12.12.4 Key Developments

    12.12.5 SWOT Analysis

    12.13 Others

    Chapter 13 Appendix

    13.1 References

    13.2 Related Reports


    LIST OF TABLES

    Table 1 Global Contraceptive Drugs Market Synopsis, 2020-2027

    Table 2 Global Contraceptive Drugs Market Estimates and Forecast, 2020-2027 (USD Million)

    Table 3 Global Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 4 Global Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 5 Global Contraceptive Drugs Market, by Region, 2020-2027 (USD Million)

    Table 6 North America: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 7 North America: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 8 US: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 9 US: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 10 Canada: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 11 Canada: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 12 Latin America: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 13 Latin America: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 14 Europe: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 15 Europe: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 16 Western Europe: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 17 Western Europe: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 18 Eastern Europe: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 19 Eastern Europe: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 20 Asia-Pacific: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 21 Asia-Pacific: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)


    Table 22 Middle East & Africa: Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Table 23 Middle East & Africa: Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Market Structure of the Global Contraceptive Drugs Market

    Figure 3 Market Dynamics of the Global Contraceptive Drugs Market

    Figure 4 Global Contraceptive Drugs Market, by Type, 2020-2027 (USD Million)

    Figure 5 Global Contraceptive Drugs Market, by Distribution Channel, 2020-2027 (USD Million)

    Figure 6 Global Contraceptive Drugs Market, by Region, 2020-2027 (USD Million)

    Figure 9 North America: Contraceptive Drugs Market Share, by Country, 2020 (%)

    Figure 7 Europe: Contraceptive Drugs Market Share, by Region, 2020 (%)

    Figure 8 Western Europe: Contraceptive Drugs Market Share, by Country, 2020 (%)

    Figure 9 Asia-Pacific: Contraceptive Drugs Market Share, by Country, 2020 (%)

    Figure 10 Middle East & Africa: Contraceptive Drugs Market Share, by Country, 2020 (%)

    Figure 11 Global Contraceptive Drugs Market: Company Share Analysis, 2020 (%)

    Figure 12 Bayer AG: Key Financials

    Figure 13 Bayer AG: Segmental Revenue

    Figure 14 Bayer AG: Regional Revenue

    Figure 15 Pfizer Inc.: Key Financials

    Figure 16 Pfizer Inc.: Segmental Revenue

    Figure 17 Pfizer Inc.: Regional Revenue

    Figure 18 Teva Pharmaceutical Industries Ltd.: Key Financials

    Figure 19 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

    Figure 20 Teva Pharmaceutical Industries Ltd.: Regional Revenue

    Figure 21 Merck & Co., Inc.: Key Financials

    Figure 22 Merck & Co., Inc.: Segmental Revenue

    Figure 23 Merck & Co., Inc.: Regional Revenue

    Figure 27 Mylan N.V.: Key Financials

    Figure 28 Mylan N.V.: Segmental Revenue

    Figure 29 Mylan N.V.: Regional Revenue

    Figure 30 Allergan Plc: Key Financials

    Figure 31 Allergan Plc: Segmental Revenue

    Figure 32 Allergan Plc: Regional Revenue

    Figure 33 Agile Therapeutics: Key Financials

    Figure 34 Agile Therapeutics: Segmental Revenue

    Figure 35 Agile Therapeutics: Regional Revenue

    Figure 36 Piramal Enterprises Ltd.: Key Financials

    Figure 37 Piramal Enterprises Ltd.: Segmental Revenue

    Figure 38 Piramal Enterprises Ltd.: Regional Revenue

    Figure 39 GlaxoSmithKline PLC: Key Financials

    Figure 40 GlaxoSmithKline PLC: Segmental Revenue

    Figure 41 GlaxoSmithKline PLC: Regional Revenue

    Figure 42 Johnson & Johnson: Key Financials

    Figure 43 Johnson & Johnson: Segmental Revenue

    Figure 44 Johnson & Johnson: Regional Revenue

    Figure 45 Novartis AG: Key Financials

    Figure 46 Novartis AG: Segmental Revenue

    Figure 47 Novartis AG: Regional Revenue

    Figure 48 Sanofi: Key Financials

    Figure 49 Sanofi: Segmental Revenue

    Figure 50 Sanofi: Regional Revenue